Skip to main content
Premium Trial:

Request an Annual Quote

Accelrys Posts 1 Percent Revenue Dip in Q2, Net Income Rises

NEW YORK (GenomeWeb News) – Accelrys today reported that revenue for its second fiscal quarter decreased by 1 percent to $20 million from $20.1 million in the prior-year period.

For the three months ended Sept. 30, the company's net income climbed 50 percent to $1.8 million, or $0.07 per diluted share, from $1.2 million, or $0.04 per diluted share, for the same quarter of the previous year.

Second-quarter product development costs decreased 5 percent to $3.6 million from $3.8 million year-over-year.

Sales and marketing costs also decreased by 5 percent, to $7.8 million from $8.2 million, while general and administrative costs rose 3 percent to $3.4 million from $3.3 million in the comparable prior-year period.

As of Sept. 30, Accelrys had $80 million in cash, cash equivalents, and marketable securities.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.